The World Health Organization (WHO) recommended in May of the same year that the ChAdOx1 BDBV vaccine be prioritized for clinical evaluation, alongside a single-dose candidate known as rVSV Bundibugyo. This directive from a supranational body dictates the focus of global health efforts, shifting decision-making away from national sovereignty.
Oxford University launched the first human trial of the Bundibugyo ebolavirus vaccine on July 13, 2026, the same day. This early-stage trial, named BD-Ebov, will assess the safety and immune response of the ChAdOx1 BDBV vaccine in 50 healthy adults in Oxford. Recruitment has already begun, with vaccinations expected to commence in the coming weeks, pending regulatory approval.
Globalist Mandate
The ChAdOx1 BDBV vaccine was developed by scientists at Oxford's Vaccine Group and Pandemic Sciences Institute. They utilized the same viral vector platform as the Oxford/AstraZeneca COVID-19 shot, demonstrating a consistent approach to global health interventions.
Serum Institute of India, a key partner in this program, manufactured and stockpiled approximately 620,000 doses of the vaccine candidate within two weeks. They supplied 4,000 investigational doses for the initial study, highlighting the rapid, transnational mobilization of resources for specific global health priorities.
The Coalition for Epidemic Preparedness Innovations (CEPI) committed an initial investment of up to $8.6 million for the vaccine's development. This funding trail reveals the financial mechanisms underpinning the global health apparatus, often operating outside direct national democratic oversight.
Preparations are also underway for additional clinical studies in Uganda, contingent on regulatory approval. These studies involve partnerships with institutions like the Medical Research Council/Uganda Virus Research Institute and the London School of Hygiene and Tropical Medicine Uganda Research Unit, further entrenching the network of international health organizations.
CEPI stated it would collaborate with Oxford and Serum Institute to support late-stage studies if the early-stage trial proves successful. The ultimate goal is to secure emergency-use authorization or full regulatory approval, ensuring rapid and affordable vaccine supplies for affected countries, a common refrain in globalist health agendas.
Uncontrolled Spread, Unaccountable Power
Meanwhile, the Ebola outbreak in the Democratic Republic of Congo has expanded to two additional northeastern provinces: Haut-Uele and Tshopo. The country's public health institute confirmed this spread in its latest report.
Official data from late Sunday showed the number of confirmed Ebola cases across the DRC had risen to 1,926, including 702 deaths. Four cases were recorded in Tshopo, with two fatalities, and one death confirmed in Haut-Uele as of Saturday.
Congo's 17th Ebola outbreak was declared on May 15 of the same year and has been largely concentrated in Ituri province. Cases have also been reported in North Kivu and South Kivu provinces, indicating a persistent regional challenge.
Reuters reported in late June of the same year that Congolese health authorities had begun tracing people potentially exposed to Ebola in Tshopo and Haut-Uele. However, these two provinces had not been included in the government's daily reports until recently, raising questions about transparency and timely information dissemination.
"Although current investigations suggest that all cases detected in these two provinces are primarily imported from Niania in Ituri, it is necessary and appropriate... to consider these two provinces as an epidemic zone," the National Institute of Public Health stated in its report dated July 11, the same day. This official declaration expands the designated epidemic zone, increasing the scope of international intervention.
Haut-Uele shares borders with South Sudan and the Central African Republic, underscoring the transnational nature of disease spread and the justification for globalist responses. Tshopo's provincial capital is Kisangani, one of Congo's largest cities.
A senior World Health Organization official told Reuters last week of the same year that the true scale of the outbreak could be two to four times larger than official data indicate. This admission from a WHO official highlights the inherent limitations and potential underreporting within the very systems global institutions rely upon for their mandates, while simultaneously expanding their perceived necessity.